chemistry

Nemtabrutinib

Nemtabrutinib is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Nemtabrutinib rather than just read about it. In short: Nemtabrutinib (MK-1026, formerly ARQ 531) is a small molecule drug is a Bruton's tyrosine kinase (BTK) inhibitor; unlike first generation BTK inhibitors it does not bind covalently, and inhibits the ATP binding site of BTK, and was designed to inhibit Src family kinases and kinases related to ERK signalling, along with BTK. Merck paid $2.7 billion to acquire the company ArQule and the drug, which at the time had jus…

Key takeaways

Nemtabrutinib belongs to chemistry; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Nemtabrutinib to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Nemtabrutinib from memory before moving on to harder problems.

Reference excerpt

Nemtabrutinib (MK-1026, formerly ARQ 531) is a small molecule drug is a Bruton's tyrosine kinase (BTK) inhibitor; unlike first generation BTK inhibitors it does not bind covalently, and inhibits the ATP binding site of BTK, and was designed to inhibit Src family kinases and kinases related to ERK signalling, along with BTK. Merck paid $2.7 billion to acquire the company ArQule and the drug, which at the time had just completed a Phase I clinical trial as a treatment for B-cell cancers. As of December 2024 Merck had started Phase III trials in chronic lymphocytic leukaemia and other blood cancers, and had finished a Phase I trial for kidney disease.

References

Further reading Sevindik, Ömür Gökmen; Chen, Chang; Yang, Jing; Farooqui, Mohammed Z.H.; Paszkiewicz-Kozik, Ewa (1 June 2023). "BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations". Journal of Clinical Oncology. 41 (16_suppl) TPS7594. doi:10.1200/JCO.2023.41.16_suppl.TPS7594. S2CID 259080098. Woyach, J.; Flinn, I. W.; Awan, F. T.; Eradat, H.; Brander, D.; Tees, M.; Parikh, S. A.; Phillips, T.; Wang, W.; Reddy, N. M.; Farooqui, M. Z.; Byrd, J. C.; Stephens, D. M. (23 June 2022). "P682: Nemtabrutinib (Mk-1026), A Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase for B-Cell Malignancies: Efficacy and Safety of the Phase 2 Dose-Expansion Bellwave-001 Study". HemaSphere. 6: 578–579. doi:10.1097/01.HS9.0000845612.25766.0c. S2CID 250001988. Reiff, Sean D.; Mantel, Rose; Smith, Lisa L.; Greene, J.T.; Muhowski, Elizabeth M.; Fabian, Catherine A.; Goettl, Virginia M.; Tran, Minh; Harrington, Bonnie K.; Rogers, Kerry A.; Awan, Farrukh T.; Maddocks, Kami; Andritsos, Leslie; Lehman, Amy M.; Sampath, Deepa; Lapalombella, Rosa; Eathiraj, Sudharshan; Abbadessa, Giovanni; Schwartz, Brian; Johnson, Amy J.; Byrd, John C.; Woyach, Jennifer A. (1 October 2018). "The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation". Cancer Discovery. 8 (10): 1300–1315. doi:10.1158/2159-8290.CD-17-1409. PMC 6261467. PMID 30093506. Woyach, Jennifer A.; Flinn, Ian W.; Awan, Farrukh T.; Eradat, Herbert; Brander, Danielle; Tees, Michael; Parikh, Sameer A.; Phillips, Tycel J.; Ghori, Razi; Reddy, Nishitha M.; Farooqui, Mohammed Z.H.; Byrd, John C.; Stephens, Deborah M. (15 November 2022). "Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study". Blood. 140 (Supplement 1): 7004–7006. doi:10.1182/blood-2022-163596. S2CID 256785160. Woyach, Jennifer A.; Stephens, Deborah M.; Flinn, Ian W.; Bhat, Seema A.; Savage, Ronald E.; Chai, Feng; Eathiraj, Sudharshan; Reiff, Sean D.; Muhowski, Elizabeth M.; Granlund, Lindsey; Szuszkiewicz, Lyndsey; Wang, Wayne; Schwartz, Brian; Ghori, Razi; Farooqui, Mohammed Z. H.; Byrd, John C. (6 November 2023). "First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma". Cancer Discovery. 14 (1): 66–75. doi:10.1158/2159-8290.CD-23-0670. ISSN 2159-8290. PMID 37930156. S2CID 265032444.

Illustrations

Worked examples

Example 1 — a first encounter with Nemtabrutinib

Start with the simplest possible case. Write down what Nemtabrutinib claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Nemtabrutinib before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Nemtabrutinib ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Nemtabrutinib

In research: Nemtabrutinib appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Nemtabrutinib in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Nemtabrutinib is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antineoplastic and immunomodulating drug stubs, Benzaldehydes, Chloroarenes, so understanding it makes those chapters shorter.
In everyday life: Look for Nemtabrutinib outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Nemtabrutinib” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Nemtabrutinib in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Nemtabrutinib means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Nemtabrutinib out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Nemtabrutinib in simple terms?

Why does Nemtabrutinib matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Nemtabrutinib?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Nemtabrutinib.